PLRZ
Polyrizon Ltd.
1W: -1.2%
1M: +1.6%
3M: +84.1%
YTD: +11.6%
1Y: -98.7%
$14.23
+0.65 (+4.79%)
After Hours: $13.44 (-0.79, -5.55%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$14.8M
52W Range2.88-2235
Volume22,874
Avg Volume86,691
Beta-6.06
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOTomer Izraeli
Employees2
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-29
Websitepolyrizon-biotech.com
5 Ha-Tidhar Street
Ra'anana 4366507
IL
Ra'anana 4366507
IL
972 9 374 0120
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Latest News
Polyrizon reports FY results: GAAP EPS of $4.90
Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Polyrizon (NASDAQ:PLRZ) Stock Price Up 1.1% – Still a Buy?
Recent Insider Trades
No insider trades found